secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rani Therapeutics Holdings, Inc. (RANI)
CIK:        0001856725
Form:       8-K
Filed at:   2023-01-09T23:59:59+00:00
Accession:  0000950170-23-000444
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

Rani Therapeutics enters license/supply deal with Celltrion for oral ustekinumab biosimilar
--------------------------------------------------------------------------------

- Rani obtains exclusive worldwide royalty-free license to Celltrion's ustekinumab biosimilar for oral delivery using Rani's platform.
- Celltrion will supply the biosimilar; Rani must purchase exclusively from Celltrion unless supply disruption.
- Celltrion has right of first negotiation for commercialization after Phase 1 data package; 30-day exercise, 90-day negotiation.
- Rani owns all data from research and development; can terminate for convenience; Celltrion can terminate if milestones not met.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1856725/000095017023000444/0000950170-23-000444-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1856725/000095017023000444/rani-20230106.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-000444

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer